| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Oleacein targets angiotensin-converting enzyme (ACE), acting as an inhibitor. It also inhibits STAT3 and activates the apoptotic machinery. These activities contribute to its potential roles in cardiovascular and metabolic diseases, as well as its anticancer and anti-inflammatory effects.
|
|---|---|
| ln Vitro |
In vitro, Oleacein has been shown to have antioxidant, anti-metastatic, anticancer, and anti-inflammatory activities. It inhibits STAT3 and activates apoptotic pathways. Its activity as an ACE inhibitor has also been demonstrated. These diverse activities make it a compound of interest for studying various disease processes.
|
| ln Vivo |
In vivo, Oleacein has oral activity and is used in research on metabolic and cardiovascular diseases. It can be used as an adjuvant to improve insulin sensitivity in humans and may play a potential role in the prevention of inflammatory disease related to atherosclerosis.
|
| Enzyme Assay |
In vitro enzyme assay protocols for Oleacein typically involve measuring its inhibition of ACE activity. This can be done using a fluorometric or spectrophotometric assay with a synthetic substrate. Its STAT3 inhibitory activity can be assessed in cell-based assays by measuring STAT3 phosphorylation.
|
| Cell Assay |
In vitro cell-based assay protocols for Oleacein involve treating various cell lines, such as cancer cells or immune cells, with the compound to assess its effects on cell viability, inflammation, and signaling pathways. For example, its anti-inflammatory activity can be assessed by measuring cytokine production in stimulated macrophages.
|
| Animal Protocol |
In vivo animal experimental protocols for Oleacein would typically involve administering the compound orally to animal models of metabolic syndrome, cardiovascular disease, or cancer. Endpoints would include blood pressure, lipid profiles, inflammatory markers, and tumor growth.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Oleacein indicate it has oral activity. It is soluble in DMSO, dichloromethane, or acetonitrile and slightly soluble in methanol. Specific parameters such as half-life and bioavailability have not been detailed in the provided literature.
|
| Toxicity/Toxicokinetics |
Toxicological data for Oleacein are not extensively detailed in the current literature. As a natural polyphenol, it is generally considered safe, but it is intended for research use only.
|
| References | |
| Additional Infomation |
2-(3,4-Dihydroxyphenyl)ethyl(E,3S)-4-formyl-3-(2-oxoethyl)hex-4-enoate has been reported in jasmine (Jasminum grandiflorum) and olive (Olea europaea), and relevant data are available.
See also: oleuropein (note moved to). Oleacein is a research-grade natural product with multiple biological activities, including antioxidant, anti-inflammatory, anticancer, and ACE inhibitory effects. It has been studied for its potential role in metabolic and cardiovascular diseases. It has not entered clinical trials as a drug but is a compound of interest for research. Its mechanism of action involves ACE inhibition and STAT3 inhibition. The compound is available exclusively for research purposes. |
| Molecular Formula |
C17H20O6
|
|---|---|
| Molecular Weight |
320.34
|
| Exact Mass |
320.125
|
| CAS # |
149183-75-5
|
| PubChem CID |
23624475
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.234±0.06 g/cm3(Predicted)
|
| Boiling Point |
551.4±50.0 °C(Predicted)
|
| LogP |
1.1
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
23
|
| Complexity |
431
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C/C=C(/C=O)\[C@@H](CC=O)CC(=O)OCCC1=CC(=C(C=C1)O)O
|
| InChi Key |
XLPXUPOZUYGVPD-VMPILDALSA-N
|
| InChi Code |
InChI=1S/C17H20O6/c1-2-13(11-19)14(5-7-18)10-17(22)23-8-6-12-3-4-15(20)16(21)9-12/h2-4,7,9,11,14,20-21H,5-6,8,10H2,1H3/b13-2-/t14-/m0/s1
|
| Chemical Name |
2-(3,4-dihydroxyphenyl)ethyl (E,3S)-4-formyl-3-(2-oxoethyl)hex-4-enoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Typically soluble in DMSO (e.g. 10 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1217 mL | 15.6084 mL | 31.2168 mL | |
| 5 mM | 0.6243 mL | 3.1217 mL | 6.2434 mL | |
| 10 mM | 0.3122 mL | 1.5608 mL | 3.1217 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
